A Phase Ib Study of The Safety And Pharmacology of Atezolizumab (Anti−Pd-L1 Antibody) Administered With Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase Ib Study of The Safety And Pharmacology of Atezolizumab (Anti−Pd-L1 Antibody) Administered With Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Interferon alpha-2b; Ipilimumab
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 17 Aug 2016 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
    • 17 Aug 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 02 Nov 2015 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top